Sacrilegious Thoughts on Adjuvant Therapy for Resected Early Stage NSCLC

Article

There's a problem in our discussions of standard treatment for patients with higher risk resected early stage NSCLC, and that is that there is a pretty clearly defined standard of care of giving typically around 4 cycles of cisplatin-based chemotherapy to reduce the risk of recurrence, but in truth, the majority of people in the real world don't get it. Still, I wouldn't want to imply that the problem is definitely that doctors aren't giving the right treatment to people who should definitely be getting it.

Podcast on Current Questions, Clinical Trials in Adjuvant Therapy for Resected NSCLC

Article

GRACE is very happy to have the opportunity to present this podcast by Dr. Heather Wakelee, medical oncologist at renowned lung cancer expert at Stanford University Cancer Center. The focus of this particular program, supported by an educational grant from GlaxoSmithKline, is on the most important research questions and clinical trials in the field of post-operative therapy for resected NSCLC.

Subscribe to ECOG 1505